Opendata, web and dolomites
H2020 projects about "carcinoma"
The page lists 51 projects related to the topic "carcinoma".
| # | |||
|---|---|---|---|
| 1 | EPoS | Elucidating Pathways of Steatohepatitis | 2015 |
| 2 | COLOStage | COLOStage : A new prognosis test for the prediction of metastasis in Colorectal Cancer and Hepatocellular Carcinoma | 2015 |
| 3 | mini-liver SCCS | Human “mini-liver” stem cell culture systems: from mechanisms behind liver cancer origin and recurrence to new therapeutic treatments | 2016 |
| 4 | TARGEPILIVER | Characterization of Key Epigenetic Targets in Hepatic Fibrosis and Hepatocellular Carcinoma Development. Generation of New Antifibrotic and Antitumoral Drugs. | 2015 |
| 5 | GENMETASTEM | GENOMIC AND METABOLIC REGULATION OF METASTATIC CANCER STEM CELLS | 2016 |
| 6 | CICCI | Characterization of Intestinal Cancer Cell Invasion | 2015 |
| 7 | HepatoRiSK | A new tumor suppressor role for RSK2 in hepatocellular carcinoma | 2015 |
| 8 | RENOIR | RENal prOgenItoRs as tools to understand kidney pathophysiology and treat kidney disorders | 2015 |
| 9 | HEPCIR | Cell circuits as targets and biomarkers for liver disease and cancer prevention | 2016 |
| 10 | HEP-CAR | Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities. | 2016 |
| 11 | ChiLTERN | Children’s Liver Tumour European Research Network | 2016 |
| 12 | PrecTherLSCC | Precision Therapies in Lung Squamous Cell Carcinoma | 2016 |
| 13 | OPTIM | Optimized drug combinations for effective cancer treatment: a personalised approach. | 2016 |
| 14 | HepatoMetaboPath | Cellular and molecular mechanisms of metabolic immune activation triggering non-alcoholic steatohepatitis (NASH) and HCC | 2016 |
| 15 | HiPerNav | High Performance Soft-tissue Navigation | 2016 |
| 16 | Foie Gras | Bioenergetic Remodeling in the Pathophysiology and Treatment of Non-Alcoholic Fatty Liver Disease | 2017 |
| 17 | mtFOIE GRAS | mitoFOIE GRAS: Non-invasive Profiling of Mitochondrial Function in Non-Alcoholic Fatty Liver Disease | 2017 |
| 18 | OPN-Can | Investigating the role of OPN-CD44 in mechanosensitive tumour invasion using biomimetic models | 2017 |
| 19 | IC_IL_EC_2017 | Investigating the effects of immunogenic chemoradiation in shaping the immune landscape of esophageal cancers | 2018 |
| 20 | Hepatocarcinoma IVM | Spatiotemporal dynamics of CD8+ T cell responses to hepatocellular carcinoma | 2017 |
| 21 | HEGEMONIC | HEpatocellular carcinoma GErmline MutatiONs ImpaCt (HEGEMONIC) | 2017 |
| 22 | FATE | Functional Biology of Hepatic CD8+ T cells | 2017 |
| 23 | HEPASPHER | Mimicking liver disease and regeneration in vitro for drug development and liver transplantation | 2017 |
| 24 | ADVaNCE | ADVerse outcome Network for non-mutagenic CarcinogEns | 2017 |
| 25 | MATADOR | MAmmary chemoresistant Tumor deAth by Directed cell ORientation | 2018 |
| 26 | HepaCheC | HepaCheC - an in vitro diagnostic assay for the early detection of liver cancer | 2018 |
| 27 | VulneraBAP1 | Mechanism and vulnerability of BAP1 loss in tumor metastasis | 2018 |
| 28 | SKin SCiENCE | Skin Keratinocyte Stem CEll proliferatioN in field CancErisation | 2018 |
| 29 | PhaseControl | How cellular suicide programmes control phase transitions in fatty liver disease and liver cancer | 2018 |
| 30 | mTORmorS | Role of mTOR signaling dysregulation in the tumor suppressor networks in hepatocellular carcinoma | 2019 |
| 31 | EDIT | Novel precision technological platforms to promote non-invasive early diagnosis, eradication and prevention of cancer relapse: proof of concept in the bladder carcinoma. | 2018 |
| 32 | HepatoPredict | A decision tool for Liver Transplantation based on molecular signature | 2018 |
| 33 | HIPShot | HBV GenetIc and Proteomic Screen | 2019 |
| 34 | COCLICAN | COllaborative Consortium for the early detection of LIver CANcer | 2018 |
| 35 | RNADIAGON | Excellence in research and development of non-coding RNA DIAGnostics in ONcology | 2019 |
| 36 | EPI-X4Health | Therapeutic potential of optimized derivatives of an endogenous CXCR4 antagonist for the treatment of cancers and inflammatory diseases | 2018 |
| 37 | RxmiRcanceR | Tumor suppressive microRNAs for cancer therapy | 2018 |
| 38 | ESCALON | European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development | 2019 |
| 39 | AURORAX | Advancing cancer detection through metabolism-based diagnostics | 2019 |
| 40 | IntratumoralNiche | Defining heterocellular signalling within the intratumoral stem cell niche of colorectal cancer | 2019 |
| 41 | Kinaddict | Vulnerability of esophageal cancer to their addiction to kinase activities: evaluation and prediction of eSCC tumors responsiveness to kinase inhibitors. | 2019 |
| 42 | EndoPos | Endosome positioning in tumour-stroma interactions | 2019 |
| 43 | MONET | Merkel cell polyomavirus Oncogenic Network | 2019 |
| 44 | MS | Unravelling the molecular and cellular mechanism of metastasis | 2020 |
| 45 | HEPCAN | A Humanized Monoclonal Anti-Claudin1 Antibody (anti-CLDN1 mAb) for Treatment of Hepatocellular Carcinoma (HCC) | 2019 |
| 46 | CSI AurkA-MYC | Conformational Shift Inducers (CSI): An atomistic level investigation of Aurora kinase A (AurkA)–MYC interaction and its distortion by CSI compounds | 2019 |
| 47 | TroyCAN | Redefining the esophageal stem cell niche – towards targeting of squamous cell carcinoma | 2020 |
| 48 | MyeFattyLiver | Unravelling the heterogeneity and functions of hepatic myeloid cells in Non-Alcoholic Fatty Liver Disease | 2019 |
| 49 | inhibiTOR | Novel selective mTORC1 inhibitors | 2020 |
| 50 | M6AQuantKit | Development and commercialization of kit for quantitative interrogation of a key RNA modification | 2020 |
| 51 | ONCO-VAX | A multifaceted cancer immunotherapy based on an immune checkpoint-modulating chimeric oncolytic virus vector in combination with a dendritic cell vaccine | 2020 |